DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

Notice of Grant Award to Waimanalo Health Center for a Project Entitled, "The Hauula Community Diabetes Screening Program"

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS. **ACTION:** Notice of grant award.

SUMMARY: The Centers for Medicare & Medicaid Services has awarded a grant entitled "The Hauula Community Diabetes Screening Program" to the Waimanalo Health Center, 41–1347 Kalanianaole Highway, Waimanalo, Hawaii 96795, in response to an

unsolicited application.

Purpose: The Waimanalo Health Center proposes to provide diabetes and related risk factor health screening as well as relevant health educational and behavioral intervention services to the geographically isolated, mostly-Samoan community of Hauula (pop. 3,651) on Oahu. Services will be targeted to its Samoan citizens but open to all residents of Hauula regardless of their ethnicity.

Total Amount of Award: \$987,317. Project Period: September 30, 2004, through March 30, 2006.

Sole Source Justification: This unsolicited proposal is responsive to the Senate Appropriations Committee's commitment to the concept of a demonstration project for American Samoans in Hawaii that will integrate social services, to include traditional health, preventive health, prevention and disease management, and address the health disparities among Native Hawaiians and other minority populations by utilizing the expertise of the Waimanalo Health Čenter. The grant will provide diabetes and related risk factor health screening, as well as relevant health educational and behavioral intervention services, to the geographically isolated, mostly-Samoan community of Hauula on Oahu, but project services will be made available to all Hauula residents regardless of their ethnicity. These services will help improve the administration and effectiveness of programs carried on or assisted under the Social Security Act and programs related thereto. The appropriation to the CMS research budget was increased to include funding to carry out this project.

FOR FURTHER INFORMATION CONTACT: Mary Kapp, Project Officer, Division of Beneficiary Research; Research and

Evaluation Group; Office of Research Development, and Information, C3–19– 07, 7500 Security Boulevard, Baltimore, MD 21244, (410) 786–0360, or Judith Norris, Grants Officer, OICS/AGG/CMS, C2–21–15, 7500 Security Boulevard, Baltimore, MD 21244, (410) 786–5130.

Authority: (Catalog of Federal Domestic Assistance Program No. 93.779 (CMS) Research, Demonstrations and Evaluations) Section 1110 of the Social Security Act.

Dated: October 29, 2004.

Mark B. McClellan,

Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 04–24765 Filed 11–4–04; 8:45 am]
BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).

A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs,

SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; (240) 276–2600 (voice), (240) 276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Mandatory Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, (414) 328–7840/ (800) 877–7016, (Formerly: Bayshore Clinical Laboratory).

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, (585) 429– 2264.

Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, (901) 794–5770/(888) 290–1150. Aegis Analytical Laboratories, Inc., 345 Hill

Ave., Nashville, TN 37210, (615) 255–2400. Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, (501) 202–2783,

AR 72205–7299, (501) 202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Rd.,

Lenexa, KS 66215–2802, (800) 445–6917. Diagnostic Services Inc., dba DSI, 12700 Westlinks Dr., Fort Myers, FL 33913, (239) 561–8200/(800) 735–5416.

Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, (229) 671–2281. DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, (206) 386–2661/(800) 898– 0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).

DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, (215) 674– 9310.

- Dynacare Kasper Medical Laboratories*, 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, (780) 451–3702/ (800) 661–9876.
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, (662) 236–2609.
- Express Analytical Labs, 3405 7th Ave., Suite 106, Marion, IA 52302, (319) 377–0500.
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, (608) 267– 6225.
- Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, (504) 361– 8989/(800) 433–3823 (Formerly: Laboratory Specialists, Inc.).
- LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, (913) 888–3927/(800) 873–8845 (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.).
- LabOne, Inc., d/b/a Northwest Toxicology, 1141 E. 3900 S., Salt Lake City, UT 84124, (801) 293–2300/(800) 322–3361 (Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.; Northwest Drug Testing, a division of NWT Inc.).
- Laboratory Corporation of America Holdings, 7207 N. Gessner Rd., Houston, TX 77040, (713) 856–8288/(800) 800–2387.
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, (908) 526– 2400/(800) 437–4986, (Formerly: Roche Biomedical Laboratories, Inc.).
- Laboratory Corporation of America Holdings, 1904 Alexander Dr., Research Triangle Park, NC 27709, (919) 572–6900/(800) 833– 3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc., CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group).
- Laboratory Corporation of America Holdings, 10788 Roselle St., San Diego, CA 92121, (800) 882–7272 (Formerly: Poisonlab, Inc.).
- Laboratory Corporation of America Holdings, 1120 Stateline Rd. West, Southaven, MS 38671, (866) 827–8042/(800) 233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).
- * The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA accredited laboratories was transferred to the U.S. HHS, with the HHS' NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 13, 2004 (69 FR 19644). After receiving DOT certification, the laboratory will be included in the monthly list of HHS certified laboratories and participate in the NLCP certification maintenance program.

- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, (715) 389–3734/ (800) 331–3734.
- MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, (905) 817–5700 (Formerly: NOVAMANN (Ontario) Inc.).
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, (651) 636–7466/ (800) 832–3244.
- MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, (503) 413–5295/(800) 950–5295.
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Dr., Minneapolis, MN 55417, (612) 725– 2088.
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, (661) 322–4250/(800) 350–3515.
- One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, (888) 747–3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, (541) 687–2134.
- Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, (800) 328– 6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory).
- Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, (509) 755–8991/(800) 541–7897, x7.
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, (913) 339–0372/(800) 821–3627.
- Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, (770) 452–1590/(800) 729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, (800) 824–6152 (Moved from the Dallas location on 03/31/ 01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).
- Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, (702) 733–7866/(800) 433– 2750 (Formerly: Associated Pathologists Laboratories, Inc.).
- Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, (610) 631– 4600/(877) 642–2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).
- Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, (800) 669– 6995/(847) 885–2010 (Formerly: SmithKline Beecham Clinical Laboratories; International Toxicology Laboratories).
- Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, (818) 989– 2520/(800) 877–2520 (Formerly: SmithKline Beecham Clinical Laboratories).
- Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236, (804) 378–9130.
- Sciteck Clinical Laboratories, Inc., 317 Rutledge Rd., Fletcher, NC 28732, (828) 650–0409.

- S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, (505) 727– 6300/(800) 999–5227.
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, (574) 234–4176, x276.
- Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, (602) 438–8507/(800) 279–0027.
- Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, (517) 364– 7400 (Formerly: St. Lawrence Hospital & Healthcare System).
- St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, (405) 272–7052.
- Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, (573) 882–1273.
- Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL 33166, (305) 593–2260.
- U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, (301) 677–7085.

Anna Marsh,

Executive Officer, SAMHSA.
[FR Doc. 04–24517 Filed 11–4–04; 8:45 am]
BILLING CODE 4160–20–P

DEPARTMENT OF HOMELAND SECURITY

Citizenship and Immigration Services [CIS No. 2336–04]

SES Performance Review Board

AGENCY: Citizenship and Immigration Services, DHS.

ACTION: Notice.

SUMMARY: This notice announces the appointment of the members of the U.S. Citizenship and Immigration Services (USCIS) Performance Review Board (PRB). The purpose of the PRB is to review and make recommendations concerning proposed performance appraisals, ratings, bonuses, pay adjustments, and other appropriate personnel actions for incumbents of Senior Executive Service (SES) positions for which the Director, USCIS, is the appointing authority. The Board will perform PRB functions for other Department of Homeland Security (DHS) SES positions if requested.

DATES: This notice is effective November 5, 2004.

FOR FURTHER INFORMATION CONTACT: Ms. Kathleen T. Hochman, Human Capital Officer, USCIS, Office of Administration, 20 Massachusetts Avenue, NW., Room 1016, Washington, DC 20529. Telephone (202) 272–1330. SUPPLEMENTARY INFORMATION: Title 5

U.S.C. 4314(c) requires each federal